Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | 10% owner | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,736 |
Reported balance
After 2026-07-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 35,736 · Balance 35,736 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 117,135 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 117,135 · Balance 117,135 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 39,038 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Grant · Acquired 39,038 · Balance 39,038 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Spouse | 127,423 |
Reported balance
After 2026-07-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-28 · Grant · Acquired 127,423 · Balance 127,423 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 20, 2022 Filed Oct 24, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 196,721 | $2.47 | $485,507.43 |
DisclosureSEC source: 0000899243-22-034034 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,362,523 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,829 | $2.50 | $529,360.67 |
DisclosureSEC source: 0000899243-22-033895 · doc4.xml · nonDerivative · entry 4 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,559,243 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 19, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,829 | $2.50 | $529,360.67 |
DisclosureSEC source: 0000899243-22-033895 · doc4.xml · nonDerivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,559,244 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 198,051 | $2.64 | $523,448.79 |
DisclosureSEC source: 0000899243-22-033895 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,771,072 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 18, 2022 Filed Oct 20, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 198,051 | $2.64 | $523,448.79 |
DisclosureSEC source: 0000899243-22-033895 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,771,073 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 195,317 | $2.64 | $515,441.56 |
DisclosureSEC source: 0000899243-22-033761 · doc4.xml · nonDerivative · entry 4 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,969,123 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 195,317 | $2.64 | $515,441.56 |
DisclosureSEC source: 0000899243-22-033761 · doc4.xml · nonDerivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,969,124 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 215,948 | $2.62 | $565,135.92 |
DisclosureSEC source: 0000899243-22-033761 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,164,440 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 215,948 | $2.62 | $565,135.92 |
DisclosureSEC source: 0000899243-22-033761 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,164,441 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 207,272 | $2.74 | $567,096.19 |
DisclosureSEC source: 0000899243-22-033674 · doc4.xml · nonDerivative · entry 4 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,380,388 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 207,271 | $2.74 | $567,093.46 |
DisclosureSEC source: 0000899243-22-033674 · doc4.xml · nonDerivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,380,389 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,066 | $2.81 | $593,095.46 |
DisclosureSEC source: 0000899243-22-033674 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,587,660 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 12, 2022 Filed Oct 14, 2022 21:30 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 211,065 | $2.81 | $593,092.65 |
DisclosureSEC source: 0000899243-22-033674 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,587,660 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 00:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 200,435 | $2.87 | $575,048.02 |
DisclosureSEC source: 0000899243-22-033512 · doc4.xml · nonDerivative · entry 4 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,798,726 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 00:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 200,435 | $2.87 | $575,048.02 |
DisclosureSEC source: 0000899243-22-033512 · doc4.xml · nonDerivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,798,725 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 00:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 213,575 | $2.88 | $614,882.43 |
DisclosureSEC source: 0000899243-22-033512 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,999,161 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 10, 2022 Filed Oct 13, 2022 00:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 213,575 | $2.88 | $614,882.43 |
DisclosureSEC source: 0000899243-22-033512 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,999,160 F1 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 343,071 | $3.12 | $1,070,930.43 |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 6 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 26,212,736 F4 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 343,072 | $3.12 | $1,070,933.56 |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 5 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,212,735 F4 · kind: Represents the number of shares sold by the Reporting Person or the Reporting Person's spouse to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person or the Reporting Person's spouse. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 12 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
| October 01, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 11 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 8 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,320,344 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass B Common Stock · Derivative | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 7 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,320,344 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.underlying_shares: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F5 · balance_after: Includes shares of Class B Common Stock that are subject to vesting conditions. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 773,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 773,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 773,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 01:06 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GiftClass A Common Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047407 · doc4.xml · nonDerivative · entry 2 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Bartholomew Canton Living Trust Disclosed balance after: 0 F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock. The donated shares remain subject to transfer restrictions in accordance with the Issuer's certificate of incorporation. Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 01:06 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | ConversionClass B Common Stock · Derivative | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-047407 · doc4.xml · derivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Bartholomew Canton Living Trust Disclosed balance after: 70,189,783 Underlying: Class A Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F3 · price: Pursuant to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. ("Legacy Ginkgo"), as contemplated by an agreement and plan of merger, dated May 11, 2021 and amended on May 14, 2021 (the "Merger Agreement"), (a) each share of Class A common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class A Common Stock; and (b) each share of Class B common stock of Legacy Ginkgo outstanding immediately prior to the effective time of the business combination was converted into approximately 49.080452 shares of the Issuer's Class B Common Stock. F4 · price: Pursuant to the Merger Agreement, each share of Class A common stock of Legacy Ginkgo, each share of Class B common stock of Legacy Ginkgo, each option of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, each award of restricted common stock of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, and each award of restricted stock units of Legacy Ginkgo under Legacy Ginkgo's stock incentive plans, in each case outstanding immediately prior to the effective time of the business combination, received a proportional amount of the approximately 188.7 million earn-out shares. F2 · derivative.exercise_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. F2 · derivative.expiration_date: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| December 06, 2021 Filed Dec 9, 2021 01:06 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | ConversionClass A Common Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-047407 · doc4.xml · nonDerivative · entry 1 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Bartholomew Canton Living Trust Disclosed balance after: 200,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions being reported herein relate to a charitable donation of shares of Class A Common Stock. The donated shares remain subject to transfer restrictions in accordance with the Issuer's certificate of incorporation. F2 · price: Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date. Read SEC document |
| November 17, 2021 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 10 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,782,354 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
| November 17, 2021 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | GrantRestricted Stock Units · Derivative | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · derivative · entry 9 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,782,354 Underlying: Class A Common Stock · Not disclosed shares Expires not disclosed F3 · derivative.exercise_price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.exercise_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.expiration_date: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · derivative.underlying_shares: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
| October 01, 2021 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 4 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 26,555,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
| October 01, 2021 Filed Oct 5, 2022 01:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | Exercise / conversionClass A Common Stock | 25,782,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-032864 · doc4.xml · nonDerivative · entry 3 Canton Barry · CIK 0001882756 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,555,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. F3 · price: Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock for each RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.